

MADRID
2017

ESMO

congress

esmo.org

ESMO 2017

**IN PARTNERSHIP
WITH THE EACR**

8-12 SEPTEMBER 2017
MADRID SPAIN

Organiser

ESMO

FOR SCIENCE
BETTER MEDICINE
BEST PRACTICE

Partner

EACR

European Association
for Cancer Research

OPENING SESSION

Fortunato Ciardiello

ESMO and Congress President






UNIVERSITÀ DEGLI STUDI
DI NAPOLI FEDERICO II



ONE DREAM ...



ESMO: 42 YEARS OF EXCELLENCE



1975-1984

THE AUDACIOUS FIRST STEPS
OF A PIONEERING SOCIETY



1985-1994

COMMITTED TO
ONCOLOGY EDUCATION



1995-2004

UNIFYING ONCOLOGY
THROUGHOUT EUROPE



**ACROSS ONCOLOGY.
WORLDWIDE.**

2005-2017

THE GLOBAL HOME FOR
ONCOLOGY PROFESSIONALS

ESMO: a member- centric society



What is the area of the rectangle?



www.dreamstime.com















ESMO STAFF



Anton Berns

EACR President



Prof. Dr. Anton Berns PhD
EACR President

Director Emeritus
Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital
Amsterdam, The Netherlands



About the EACR

- Established in 1968
- Over 10,000 members in 101 countries
- 14 affiliated National Societies (ASEICA etc.)

VISION

Science drives prevention and cures of cancer.

MISSION

EACR galvanises excellence in multidisciplinary cancer research by:

Fostering interactions between researchers

Organising cutting edge scientific meetings

Educating the next generation of cancer scientists

Campaigning for cancer research with funders, policy-makers and society


Members stats

Would you recommend EACR membership to others?


98% said 'Yes'



Level of seniority



Where do members work?



Which areas do members work in?

*Participants could select multiple options

Complementarity with ESMO

- Cancer research is a two-way street: Bench < ----- > Bedside.
Increasingly information from clinical trials lead to new basic research questions.
- Interaction between scientists along this trajectory is key for accelerating progress.
- **Fostering** this interaction, **learning** each others language, and jointly **formulating new research questions**, is what we aspire to in the **ESMO –EACR partnership**.
- We are working to the same **goal: improving prevention, diagnosis, and treatment of cancer**.
- By working together we will make progress **faster**.



GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE



EACR

European Association
for Cancer Research

Miguel Martín Jiménez

ESMO 2017 Local Officer



ESMO 2017 LOCAL OFFICER ADDRESS

Prof. Miguel Martín Jiménez

ESMO 2017 Local Officer

Madrid, 8 September 2017

SEOM (Spanish Society of Medical Oncology), which I have the honor of presiding, is a National Scientific society in close collaboration with ESMO

SEOM has 2.352 members

1.283 Board-certificated Spanish Medical Oncologists are actually working in Spain

378 Spanish Oncologists are members of ESMO and this number is increasing each year

79 Medical Oncology Services are accredited for training residents in Medical Oncology in our country

43 Spanish speakers in ESMO2017 (8% of total speakers)

150 Spanish abstracts accepted in ESMO2017 (5% of total abstracts)

23.000 total attendees to ESMO2017 (1.300 are Spanish)

130 Origin countries of attendees to ESMO2017



FRI 9/8



26° /16°

Partly sunny

Hist. Avg.
28°/15°

SAT 9/9



30° /17°

Mostly sunny

Hist. Avg.
28°/15°

SUN 9/10



30° /16°

Mostly cloudy

Hist. Avg.
27°/14°

MON 9/11



30° /16°

Sun and
some clouds

Hist. Avg.
27°/14°

TUE 9/12



30° /19°

Brilliant
sunshine

Hist. Avg.
27°/14°

Underground

<http://www.planometromadrid.org>

Line 8-Estación Feria de Madrid

Bus lines:

- Line 112-Feria de Madrid - Bº Aeropuerto.
- Line 122-Avda. de América-Feria de Madrid.
- Line 828-Universidad Autónoma-Alcobendas-Feria de Madrid.



WELCOME TO MADRID!

Alberto Sobrero

ESMO Scientific Co-Chair



ESMO SCIENTIFIC ADDRESS

Alberto Sobrero

ESMO 2017 Scientific Co-Chair

Madrid, 8 September 2017

ESMO 2017 SCIENTIFIC ADDRESS

Alberto Sobrero

ESMO 2017 Scientific Co-Chair

Madrid, 8 September 2017

ESMO 2017 SCIENTIFIC STEERING COMMITTEE

ESMO 2017 and Congress President

Fortunato Ciardiello, Naples, Italy

ESMO 2017 Scientific Committee Co-Chairs

ESMO: Alberto Sobrero, Genoa, Italy

EACR: Richard Marais, Manchester, UK

ESMO 2017 Educational Chair

Andrés Cervantes, Valencia, Spain

ESMO 2017 Local Officer

Miguel Martín Jiménez, Madrid, Spain

ESMO 2017 Press Officer

Solange Peters, Lausanne, Switzerland

ESMO 2017 SCIENTIFIC COMMITTEE TRACK CHAIRS

Basic science: Anton Berns, Amsterdam, Netherlands and Christof von Kalle, Heidelberg, Germany; **Breast cancer, early stage:** Nadia Harbeck, Munich, Germany; **Breast cancer, metastatic:** Fabrice André, Villejuif, France; **CNS tumours:** Michael Weller, Zurich, Switzerland; **Developmental therapeutics:** Jan Schellens, Amsterdam, Netherlands; **Gastrointestinal tumours, colorectal:** Volker Heinemann, Munich, Germany; **Gastrointestinal tumours, non-colorectal:** Eric Van Cutsem, Leuven, Belgium; **Genitourinary tumours, prostate:** Johann de Bono, Sutton, UK; **Genitourinary tumours, non-prostate:** Bernard Escudier, Villejuif, France; **Gynaecological cancers:** Domenica Lorusso, Milan, Italy; **Haematological malignancies:** Mariano Provencio, Madrid, Spain; **Head and neck cancer:** Jean-Pascal Machiels, Brussels, Belgium; **Immunotherapy of cancer:** Inge Marie Svane, Herlev, Denmark; **Melanoma and other skin tumours:** Reinhard Dummer, Zurich, Switzerland; **NETs and endocrine tumours:** Michel Ducreux, Villejuif, France; **Non-metastatic NSCLC and other thoracic malignancies:** Pilar Garrido, Madrid, Spain; **NSCLC, metastatic:** Rafal Dziadziuszko, Gdansk, Poland; **Public health and health economics:** Paolo G. Casali, Milan, Italy; **Sarcoma:** Jean-Yves Blay, Lyon, France; **Supportive and palliative care:** Matti Aapro, Genolier, Switzerland; **Translational research:** Charles Swanton, London, UK (ESMO) and Joan Seoane, Barcelona, Spain (EACR); **ESMO Patient Advocacy Working Group:** Bettina Ryll, Uppsala, Sweden; **ESMO Young Oncologists Committee:** Matthias Preusser, Vienna, Austria

**Representing approx. 280 Scientific Committee members
across the 21 tracks
incl. 40 Educational Committee members
on behalf of the full ESMO Faculty**



THE MOST EXCITING ESMO CONGRESS EVER

- ❖ Four full days of Congress Programme
- ❖ Up to twelve sessions in parallel
- ❖ Three Presidential sessions, one each on Saturday, Sunday and Monday, presenting 7 Late-Breaking Abstracts (LBA) and 3 important practice-changing non-LBAs
- ❖ More than 520 invited speakers
- ❖ Programme content with high-quality content for all oncology professionals



Three Keynote
lectures

Four full Award
lectures

16 Joint Symposia and 13
ad-hoc Special interest
sessions

Extended Young Oncologist
programme including new
Mentor sessions

NOT-TO-MISS!

Full sessions across
21 tracks

56 Industry satellites,
including 2 ESMO
Colloquia

Full Patient Advocacy
track over 4 days

CLINICAL TRIALS REPRESENTED

Phase I

101

Phase I/II

39

Phase II

177

Phase II/III

4

Phase III

161



ESMO 2017: LATE-BREAKING ABSTRACTS NOT TO MISS

LBA2_PR Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

LBA4_PR RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

2360_PR MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer

9280_PR Neoadjuvant chemotherapy followed by surgery (NACT-surgery) versus concurrent cisplatin and radiation therapy (CTRT) in patients with stage IB2 to IIB squamous carcinoma of cervix: A randomized controlled trial (RCT)

LBA7_PR BRIM8: A randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence


LBA6_PR COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma

LBA8_PR Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)


LBA5 CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups




SCIENTIFIC AND EDUCATIONAL PROGRAMME AT A GLANCE



ESMO 2017 EDUCATIONAL PROGRAMME




- Educational sessions 23
- Challenge your expert 21
- Clinical Practice Guidelines 2




ESMO 2017 SCIENTIFIC PROGRAMME

Non-abstract related



- Keynote sessions, 3
- Multidisciplinary patient cases, 18
- Young Oncologists sessions, 8
- Controversy sessions, 5
- Patient Advocacy sessions, 9
- Special Symposia, 21
- Joint symposia, 16
- Ad-hoc special sessions, 13
- Congress Highlights, 2

Non-abstract related




- Presidential Symposia, 3
- Proffered paper sessions, 24
- Poster discussion sessions, 20
- Combined PP/PD session, 1
- Poster sessions, 3

146 sessions – 75% of the programme

ESMO 2017 ABSTRACT SUBMISSION


3,260 submitted, 1'736 accepted

Regular abstracts: 1,681



■ Oral presentation, 82 ■ Poster discussion, 202 ■ Poster display, 1397


Late-breaking abstracts: 55




■ Oral presentation 37 ■ Poster discussion 18

SATELLITE SYMPOSIA / ESMO COLLOQUIA

ESMO 2016 Copenhagen 55 slots



ESMO 2017 Madrid 56 slots



A decorative geometric pattern in the top-left corner, composed of various colored triangles and polygons in shades of red, orange, yellow, and teal.

**Thank you
and
have a great Congress experience!**

A decorative geometric pattern along the bottom edge, featuring a mix of red, orange, yellow, and teal shapes.

Richard Marais

EACR Scientific Co-Chair



EACR SCIENTIFIC ADDRESS

Professor Richard Marais

EACR Scientific Co-Chair

Madrid, 8 September 2017

ESMO 2017

IN PARTNERSHIP WITH

EACR
European Association
for Cancer Research

MADRID SPAIN
8-12 SEPTEMBER 2017

Cases



New cases of worldwide
cancer, 2012

Common cancers





More than 4 in 10 of
new cases of cancer
are lung, female breast,
bowel or prostate
cancer, 2012, worldwide

Projection to 2030



Cancer incidence rates
projected increase
2012-2030, worldwide





THANK YOU!

THANK YOU!

Jean-Charles Soria
Annals of Oncology Editor-in-Chief





ESMO AWARD 2017

to...

Miguel Martín Jiménez

President of the Spanish Society of Medical Oncology (SEOM)

Professor of Medicine at the Complutense University, Madrid, Spain

Head of the Medical Oncology Service at the Hospital General Universitario Gregorio Marañón, in Madrid, Spain



**ESMO Award
2017**